Core Insights - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through innovative drug delivery systems [1][3] - The company will present at the Oppenheimer 35 Annual Healthcare Life Sciences Conference on February 11-12, 2025, with on-demand access starting February 12, 2025 [2] Company Overview - PolyPid utilizes its proprietary PLEX technology for controlled, prolonged-release therapeutics, allowing for precise drug delivery over days to months [3] - The lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing abdominal colorectal surgical site infections [3] - PolyPid is also in preclinical stages testing OncoPLEX for treating solid tumors, starting with glioblastoma [3]
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference